This randomised, triple-blind, placebo-controlled crossover trial (n=18) will investigate the acute analgesic (anti-pain) effects of N,N-dimethyltryptamine (DMT) on experimentally induced acute nociceptive pain, hyperalgesia, and allodynia in healthy participants.
This is a randomized, counter-balanced three-period crossover in healthy volunteers comparing continuous IV DMT infusion, racemic ketamine infusion, and saline placebo using a validated electrical stimulation pain model to probe nociception, hyperalgesia and allodynia.
DMT is administered as a controllable continuous intravenous infusion (1.2 mg/min) allowing rapid adjustment and termination; ketamine (1.0 mg/min) serves as an active comparator and saline as placebo. Outcomes include acute pain intensity and secondary measures of pain sensitisation.
Continuous intravenous infusion of DMT (controllable, short half-life) in a single session within a three-period crossover.
Continuous IV infusion at 1.2 mg/min; rapidly adaptable and terminable psychedelic state.
Racemic ketamine active comparator infusion in crossover.
Racemic ketamine infusion at 1.0 mg/min as positive control.
Saline placebo infusion in crossover.
Saline infusion (placebo).